NCCN gives category 2b recommendation for either ER+ or ER-, HER2+ tumors, from the Tolaney NEJM 2015 paper with trastuzumab/paclitaxel. However, only 68 patients (16.7%) were pT1a and prior registries show 5-year distant recurrence free survivals anywhere from 86-93%.
How would you deal with a tumor of 3 mm in a 34 yo...
If she is ER-, 3mm, 34 years old, I think you can ...
I would assume you mean these with NCCN language: ...